Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
Deal Watch: MacroGenics Offloads Margenza To TerSera As Focus Shifts To Pipeline
Lilly unit explores external innovation with insitro and Qinotto, plus deals involving Novartis/3BP, Eterna/Factor, Molecure/Ocean, Bayer/MOMA, Virios/Wex and more.
More from Deal Watch
More from Scrip
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.